Thyrocare Technologies cash flow

Latest FY26

Cash from operations: ₹213cr+11.5% on FY25
Capital spending: ₹20.9cr−53.5% on FY25
Free cash flow: ₹192cr+31.4% on FY25
Cash from financing: −₹170cr−₹130 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	58.6	55.3	47.0	38.7
	—	−1.9	0.0	0.0	0.0
	—	2.8	3.1	4.2	2.4
	—	−3.1	−2.0	−1.0	−1.4
	—	−2.6	−1.1	−5.8	0.0
	—	24.1	0.0	0.0	0.0
	—	1.3	24.5	0.0	0.0
	—	0.0	0.0	0.0	−5.4
	—	0.0	−7.7	16.7	21.2
	—	−1.9	1.0	−19.9	−3.1
	—	−1.0	−30.8	32.8	−1.4
	—	0.0	0.0	0.0	5.2
	—	−5.1	0.0	0.0	−0.4
	—	2.7	−15.4	2.2	0.0
	—	−4.1	0.0	0.0	0.0
	—	−10.9	36.1	16.1	8.8
	—	0.0	0.0	0.0	0.1
	—	0.0	1.3	0.0	−2.7
	—	−3.1	20.3	0.4	0.0
	—	0.0	0.0	0.9	0.0
	—	5.6	1.3	7.4	9.5
	—	0.0	0.0	0.0	−1.0
Cash from operating activities
	199	211	147	95.6	87.4
	—	61.6	85.8	101	70.4
	—	273	233	197	158
	—	59.8	41.4	29.0	28.5
	—	213	191	168	129
Cash from investing activities
	—	20.9	44.9	61.6	43.7
	—	5.4	0.0	0.7	2.1
	—	0.0	0.0	0.0	193
	—	0.0	0.0	8.0	185
	—	10.6	6.6	19.9	0.0
	—	0.0	8.2	0.0	0.0
	—	0.0	0.0	3.5	0.0
	—	0.0	11.3	0.0	0.0
	—	3.1	2.0	1.0	1.3
	—	0.0	0.0	0.0	−7.2
	—	−23.0	−52.5	−91.3	−39.0
Cash from financing activities
	—	0.0	0.0	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	0.0	0.0	−1.2	0.0
	—	0.0	0.0	28.6	0.0
	—	0.0	21.6	7.0	0.0
	—	21.2	13.1	5.7	7.8
	—	0.0	0.4	6.6	0.0
	—	148	95.3	95.3	79.4
	—	0.0	0.0	0.0	0.9
	—	−170	−130	−84.8	−86.2
	—	20.6	8.4	−8.5	4.1
	—	20.6	8.4	−8.5	4.1
	—	—	—	9.3	17.8
Reference items
	299	262	190	137	120
	32.2%	31.6%	27.7%	24.0%	22.8%
	192	192	146	106	85.7
	—	—	124	121	—
	₹12.09	₹12.09	₹9.20	₹6.66	₹5.38
	42.66×	—	—	—	—
	—	1.31×	2.11×	2.41×	2.01×
	—	59.8	41.4	29.0	28.5
	—	—	0.4	6.6	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

THYROCARE₹515.50

Thyrocare Technologies Ltd.

· Pharma & Health

₹ CrorePeersLALPATHLAB METROPOLIS VIJAYA SUPRIYA VIYASH STAR SPARC YATHARTHMcap ₹8,205 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	38.7	47.0	55.3	58.6	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.0	-1.9	—
+ Finance Costs	2.4	4.2	3.1	2.8	—
+ Interest Income	-1.4	-1.0	-2.0	-3.1	—
+ Fair Value (Gains) / Losses	0.0	-5.8	-1.1	-2.6	—
+ Share-based Payments	0.0	0.0	0.0	24.1	—
+ Other Non-cash Items	0.0	0.0	24.5	1.3	—
+ Other — Cash Effects are Investing / Financing	-5.4	0.0	0.0	0.0	—
+ Other Reconciling Items	21.2	16.7	-7.7	0.0	—
Changes in Working Capital
+ Inventories	-3.1	-19.9	1.0	-1.9	—
+ Trade Receivables — Current	-1.4	32.8	-30.8	-1.0	—
+ Other Financial Assets — Current	5.2	0.0	0.0	0.0	—
+ Other Financial Assets — Non-current	-0.4	0.0	0.0	-5.1	—
+ Other Current Assets	0.0	2.2	-15.4	2.7	—
+ Other Non-current Assets	0.0	0.0	0.0	-4.1	—
+ Trade Payables — Current	8.8	16.1	36.1	-10.9	—
+ Other Financial Liabilities — Current	0.1	0.0	0.0	0.0	—
+ Other Financial Liabilities — Non-current	-2.7	0.0	1.3	0.0	—
+ Other Current Liabilities	0.0	0.4	20.3	-3.1	—
+ Other Non-current Liabilities	0.0	0.9	0.0	0.0	—
+ Provisions — Current	9.5	7.4	1.3	5.6	—
+ Provisions — Non-current	-1.0	0.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	87.4	95.6	146.9	211.5	199.4
+ Total Adjustments (incl. Working Capital)	70.4	101.0	85.8	61.6	—
Cash from Operations (pre-tax)	157.8	196.6	232.7	273.1	—
+ Income Taxes Paid	28.5	29.0	41.4	59.8	—
Cash from Operating Activities	129.3	167.6	191.3	213.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	43.7	61.6	44.9	20.9	—
+ Disp of Fixed Assets	2.1	0.7	0.0	5.4	—
+ Disp of Intangible Assets	193.2	0.0	0.0	0.0	—
+ Acq of Investment Property	184.8	8.0	0.0	0.0	—
+ Acq of Other Long-term Assets	0.0	19.9	6.6	10.6	—
+ Disp of Other Long-term Assets	0.0	0.0	8.2	0.0	—
+ Acq of Interests in Joint Ventures	0.0	3.5	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	11.3	0.0	—
+ Interest Received — Investing	1.3	1.0	2.0	3.1	—
+ Other Inflows / (Outflows) — Investing	-7.2	0.0	0.0	0.0	—
Cash from Investing Activities	-39.0	-91.3	-52.5	-23.0	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.0	0.0	—
+ Payments for Other Equity Instruments	0.0	-1.2	0.0	0.0	—
+ Proceeds from Borrowings	0.0	28.6	0.0	0.0	—
+ Repayment of Borrowings	0.0	7.0	21.6	0.0	—
+ Payment of Lease Liabilities	7.8	5.7	13.1	21.2	—
+ Interest Paid	0.0	6.6	0.4	0.0	—
+ Dividends Paid	79.4	95.3	95.3	148.4	—
+ Other Inflows / (Outflows) — Financing	0.9	0.0	0.0	0.0	—
Cash from Financing Activities	-86.2	-84.8	-130.4	-169.6	—
Net Changes in Cash (pre-FX)	4.1	-8.5	8.4	20.6	—
Net Changes in Cash	4.1	-8.5	8.4	20.6	—
Closing Cash	17.8	9.3	—	—	—
Reference Items
EBITDA	120.1	137.4	190.4	262.0	299.5
EBITDA Margin %	22.79	24.03	27.69	31.61	32.19
Free Cash Flow (CFO − Capex)	85.7	106.1	146.4	192.4	192.4
Free Cash Flow to Equity	—	121.0	124.4	—	—
Free Cash Flow per Basic Share	5.38	6.66	9.20	12.09	12.09
Price to Free Cash Flow	—	—	—	—	42.66
Cash Flow to Net Income	2.01	2.41	2.11	1.31	—
Cash Paid for Taxes	28.5	29.0	41.4	59.8	—
Cash Paid for Interest	—	6.6	0.4	—	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.